OGN (Organon) Moat Score: 5/10 (As of Jun. 28, 2026)


OGN Organon & Co OGN
71 GF Score
Price $13.50
GF Value $14.55
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Organon Moat Score?

Organon OGN +0.22% 71 Moat Score is 5 as of Jun. 28, 2026. GuruFocus rates OGN with a GF Score™ of 71/100 and a GF Value™ of $14.55 (Fairly Valued). The stock has 10 warning signs investors should review. Among 1,033 Drug Manufacturers companies, Organon ranks better than 94.68% on this metric.

Organon has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Organon has Narrow Moat: Organon & Co benefits from valuable intellectual property and a strong distribution network in the pharmaceutical industry. While it has a solid market position, it lacks significant customer switching costs and brand strength, resulting in a solid narrow moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Organon might have Narrow Moat - Solid narrow moat.

Organon  (NYSE:OGN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Organon Moat Score Related Terms

OGN vs AMRN, SCLX, MIRA: Moat Score Comparison

For the Drug Manufacturers - General subindustry, Organon's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Organon Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organon's Moat Score distribution charts can be found below:

* The bar in red indicates where Organon's Moat Score falls into.


OGN
71GF Score
Organon & Co OGN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Organon (OGN) has a Moat Score of 5 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Organon ranks #55 out of 1033 companies in the Drug Manufacturers industry, placing it in the top 5.3%.
Is Organon's Moat Score too high?
Organon's current Moat Score is 5. Based on the distribution chart, Organon ranks #55 out of 1033 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Organon has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Organon's Moat Score compare to AMRN and SCLX?
According to the Drug Manufacturers industry distribution chart, Organon ranks #55 out of 1033 companies for Moat Score. This places Organon in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Organon's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organon stock overvalued right now?
Based on GuruFocus' analysis, Organon (OGN) is currently considered Fairly Valued. The stock's GF Value™ is $14.55, compared to a current price of $13.50 — trading 7.2% below its estimated fair value. The current Moat Score is 5. Organon's overall GF Score™ is 71/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Organon (OGN), the current Moat Score is 5 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organon (OGN) Overvalued in 2026?

Based on GuruFocus' analysis, Organon stock appears to be undervalued. The current stock price of $13.50 is trading 7.2% below its estimated GF Value™ of $14.55. GuruFocus considers Organon to be Fairly Valued.

Key valuation signals for OGN:

  • Moat Score: 5
  • GF Value™: $14.55 vs. price of $13.50 (7.2% below fair value)
  • GF Score™: 71/100 with 10 warning signs

No single metric tells the full story. See the OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Organon Business Description

Address 30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
71GF Score

Get the complete analysis for OGN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.50
Price
$14.55
GF Value